Parenteral nutrition at the palliative phase of advanced cancer: the ALIM-K study protocol for a randomized controlled trial

Lionel Pazart, Elodie Cretin, Ghislain Grodard, Cecile Cornet, Florence Mathieu-Nicot, Franck Bonnetain, Mariette Mercier, Patrice Cuynet, Carole Bouleuc, Regis Aubry, ALIM-K study investigational group, Lionel Pazart, Elodie Cretin, Ghislain Grodard, Cecile Cornet, Florence Mathieu-Nicot, Franck Bonnetain, Mariette Mercier, Patrice Cuynet, Carole Bouleuc, Regis Aubry, ALIM-K study investigational group

Abstract

Background: Malnutrition is a common complication in patients at the palliative stage of cancer. During the curative phase of cancer, optimal enteral or parenteral nutrition intake can reduce morbidity and mortality, and improve quality of life. When the main goal of treatment becomes palliative, introduction of artificial nutrition is controversial. Although scientific societies do not recommend the introduction of artificial nutrition in all cases of malnutrition, especially in hypophagic patients if their life expectancy is shorter than 2 months, considerable differences in the use of parenteral nutrition in nonsurgical oncology practice are noted around the world. One explanation is a paucity of well-conducted randomized controlled trials in these situations, and consequently, the risk/benefit ratio of parenteral nutrition and its impact on quality of life in palliative care remains uncertain.

Methods/design: The ALIM-K study is a French national multicenter randomized controlled trial designed to evaluate the effectiveness of parenteral nutrition, versus an exclusive oral-feeding supply, on the quality of life of malnourished patients who have a functional digestive tube and who are at the palliative phase of advanced cancer with a life expectancy of more than 2 months.

Discussion: This article presents the methodologic options chosen for our study, and in particular, the choice of the Zelen method of randomization, the definition of the main end point (quality of life), the choice of comparator (oral feeding), and the inclusion criteria (life expectancy of more than 2 months), which are all critical points in building a randomized controlled trial in the setting of palliative care.

Trial registration: This study was registered with the clinical trials database ClinicalTrials.gov on May 27, 2014, under the number NCT02151214.

References

    1. Pressoir M, Desne S, Berchery D, Rossignol G, Poiree B, Meslier M, Traversier S, Vittot M, Simon M, Gekiere JP, Meuric J, Serot F, Falewee MN, Rodrigues I, Senesse P, Vasson MP, Chelle F, Maget B, Antoun S, Bachmann P. Prevalence, risk factors and clinical implications of malnutrition in French Comprehensive Cancer Centres. Br J Cancer. 2010;102:966–971. doi: 10.1038/sj.bjc.6605578.
    1. Corish CA, Kennedy NP. Protein-energy undernutrition in hospital in-patients. Br J Nutr. 2000;83:575–591. doi: 10.1017/S000711450000074X.
    1. Woo J, Chan SM, Mak YT, Swaminathan R. Biochemical predictors of short term mortality in elderly residents of chronic care institutions. J Clin Pathol. 1989;42:1241–1245. doi: 10.1136/jcp.42.12.1241.
    1. Arends J, Bodoky G, Bozzetti F, Fearon K, Muscaritoli M, Selga G, van Bokhorst-de van der Schueren MA, von Meyenfeldt M, Zürcher G, Fietkau R, Aulbert E, Frick B, Holm M, Kneba M, Mestrom HJ, Zander A, DGEM (German Society for Nutritional Medicine) ESPEN Guidelines on Enteral Nutrition: non-surgical oncology. Clin Nutr. 2006;25:245–259. doi: 10.1016/j.clnu.2006.01.020.
    1. Bozzetti F, Arends J, Lundholm K, Micklewright A, Zurcher G, Muscaritoli M. ESPEN guidelines on parenteral nutrition: non-surgical oncology. Clin Nutr. 2009;28:445–454. doi: 10.1016/j.clnu.2009.04.011.
    1. Cozzaglio L, Balzola F, Cosentino F, DeCicco M, Fellagara P, Gaggiotti G, Gallitelli L, Giacosa A, Orban A, Fadda M, Gavazzi C, Pirovano F, Bozzetti F. Outcome of cancer patients receiving home parenteral nutrition: Italian Society of Parenteral and Enteral Nutrition (S.I.N.P.E.) JPEN J Parenter Enteral Nutr. 1997;21:339–342. doi: 10.1177/0148607197021006339.
    1. Piot E, Leheup BF, Goetz C, Quilliot D, Niemier JY, Wary B, Ducrocq X. Am J Hosp Palliat Care. 2014. Caregivers confronted with the withdrawal of artificial nutrition at the end of life: prevalence of and reasons for experienced difficulties.
    1. Bachmann P, Marti-Massoud C, Blanc-Vincent MP, Desport JC, Colomb V, Dieu L, Kere D, Melchior JC, Nitenberg G, Raynard B, Roux-Bournay P, Schneider S, Senesse P. Summary version of the Standards, Options and Recommendations for palliative or terminal nutrition in adults with progressive cancer (2001) Br J Cancer. 2003;89:S107–10. doi: 10.1038/sj.bjc.6601092.
    1. Bachmann P, Desport JC. [Nutrition in palliative situations] In: Cano N, Barnoud D, Schneider SM, Vasson MP, Hasselmann M, Leverve X, editors. Traité de Nutrition Artificielle de l'Adulte. 3. Paris: Springer; 2007. pp. 1129–1136.
    1. Orrevall Y, Tishelman C, Permert J, Lundstrom S. A national observational study of the prevalence and use of enteral tube feeding, parenteral nutrition and intravenous glucose in cancer patients enrolled in specialized palliative care. Nutrients. 2013;5:267–282. doi: 10.3390/nu5010267.
    1. Oh do Y, Kim JH, Lee SH, Kim DW, Im SA, Kim TY, Heo DS, Bang YJ, Kim NK. Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. Support Care Cancer. 2007;15:631–636. doi: 10.1007/s00520-006-0184-9.
    1. Lundholm K, Daneryd P, Bosaeus I, Korner U, Lindholm E. Palliative nutritional intervention in addition to cyclooxygenase and erythropoietin treatment for patients with malignant disease: effects on survival, metabolism, and function. Cancer. 2004;100:1967–1977. doi: 10.1002/cncr.20160.
    1. Groenvold M, Petersen MA, Aaronson NK, Arraras JI, Blazeby JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Bjorner JB. The development of the EORTC QLQ-C15-PAL: a shortened questionnaire for cancer patients in palliative care. Eur J Cancer. 2006;42:55–64. doi: 10.1016/j.ejca.2005.06.022.
    1. Zelen M. A new design for randomized clinical trials. N Engl J Med. 1979;300:1242–1245. doi: 10.1056/NEJM197905313002203.
    1. Blackburn GL, Bistrian BR, Maini BS, Schlamm HT, Smith MF. Nutritional and metabolic assessment of the hospitalized patient. JPEN J Parenter Enteral Nutr. 1977;1:11–22. doi: 10.1177/014860717700100111.
    1. Hasselmann M, Alix E. [Tools and screening procedures for malnutrition and risk of malnutrition in the hospital setting] Nutr Clin Metabol. 2003;17:218–226. doi: 10.1016/j.nupar.2003.09.004.
    1. Kondrup J, Allison SP, Elia M, Vellas B, Plauth M. ESPEN guidelines for nutrition screening 2002. Clin Nutr. 2003;22:415–421. doi: 10.1016/S0261-5614(03)00098-0.
    1. Roza AM, Shizgal HM. The Harris Benedict equation reevaluated: resting energy requirements and the body cell mass. Am J Clin Nutr. 1984;40:168–182.
    1. Senesse P, Vasson MP, Groupe de Travail de la Société francophone de nutrition clinique et métabolisme SFNEP oncology nutrition guidelines: When and how to assess the nutritional status? How to diagnose undernutrition and severe undernutrition? Which situations are most at risk for undernutrition? Nutr Clin Metabol. 2012;26:165–188. doi: 10.1016/j.nupar.2012.10.004.
    1. Dall'Osto H, Simard M, Delmont N, Mann G, Hermitte M, Cabrit R, Theodore C. [Parenteral nutrition: indications, modalities and complications] EMC Hépato-Gastroenterol. 2005;2:223–248. doi: 10.1016/j.emchg.2005.04.001.
    1. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139–144.
    1. Steinhauser KE, Clipp EC, Bosworth HB, McNeilly M, Christakis NA, Voils CI, Tulsky JA. Measuring quality of life at the end of life: validation of the QUAL-E. Palliat Support Care. 2004;2:3–14. doi: 10.1017/S1478951504040027.
    1. Poirier AL, Kwiatkowski F, Commer JM, D'Aillieres B, Berger V, Mercier M, Bonnetain F. Health-related quality of life in cancer patients at the end of life, translation, validation, and longitudinal analysis of specific tools: study protocol for a randomized controlled trial. Trials. 2012;13:39. doi: 10.1186/1745-6215-13-39.
    1. Fleming TR, Harrington DP, O'Brien PC. Designs for group sequential tests. Control Clin Trials. 1984;5:348–361. doi: 10.1016/S0197-2456(84)80014-8.
    1. Matts J, McHuh R. Randomization and efficiency in Zelen’s Single-Consent Design. Biometrics. 1987;43:885–894. doi: 10.2307/2531542.
    1. Diggle PJ, Kenward MG. Informative drop-out in longitudinal data analysis. J R Stat Soc Ser C (Appl Stat) 1994;43:49–93.
    1. Rubin DB. Inference and missing data. Biometrika. 1976;63:581–592. doi: 10.1093/biomet/63.3.581.
    1. Anota A, Hamidou Z, Paget-Bailly S, Chibaudel B, Bascoul-Mollevi C, Auquier P, Westeel V, Fiteni F, Borg C, Bonnetain F. Qual Life Res. 2013. Time to health-related quality of life score deterioration as a modality of longitudinal analysis for health-related quality of life studies in oncology: do we need RECIST for quality of life to achieve standardization?
    1. Bonnetain F, Dahan L, Maillard E, Ychou M, Mitry E, Hammel P, Legoux JL, Rougier P, Bedenne L, Seitz JF. Time until definitive quality of life score deterioration as a means of longitudinal analysis for treatment trials in patients with metastatic pancreatic adenocarcinoma. Eur J Cancer. 2010;46:2753–2762. doi: 10.1016/j.ejca.2010.07.023.
    1. Brookmeyer R, Crowley J. A k-sample median test for censored data. J Am Stat Assoc. 1982;77:433–440.
    1. Pencina MJ, D'Agostino RB, Sr, D'Agostino RB, Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157–172. doi: 10.1002/sim.2929.
    1. Pepe MS, Feng Z, Gu JW. Comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Stat Med (doi:10.1002/sim.2929) Stat Med. 2008;27:173–181. doi: 10.1002/sim.2991.
    1. Koretz RL, Avenell A, Lipman TO, Braunschweig CL, Milne AC. Does enteral nutrition affect clinical outcome? A systematic review of the randomized trials. Am J Gastroenterol. 2007;102:412–429. doi: 10.1111/j.1572-0241.2006.01024.x.
    1. Ryu J, Nam BH, Jung YS. Clinical outcomes comparing parenteral and nasogastric tube nutrition after laryngeal and pharyngeal cancer surgery. Dysphagia. 2009;24:378–386. doi: 10.1007/s00455-009-9213-4.
    1. Silander E, Jacobsson I, Berteus-Forslund H, Hammerlid E. Energy intake and sources of nutritional support in patients with head and neck cancer: a randomised longitudinal study. Eur J Clin Nutr. 2013;67:47–52. doi: 10.1038/ejcn.2012.172.
    1. Zaloga GP. Parenteral nutrition in adult inpatients with functioning gastrointestinal tracts: assessment of outcomes. Lancet. 2006;367:1101–1111. doi: 10.1016/S0140-6736(06)68307-4.
    1. Zhang Y, Gu Y, Guo T, Li Y, Cai H. Perioperative immunonutrition for gastrointestinal cancer: a systematic review of randomized controlled trials. Surg Oncol. 2012;21:e87–e95. doi: 10.1016/j.suronc.2012.01.002.
    1. Rabow MW, Dibble SL, Pantilat SZ, McPhee SJ. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. Arch Intern Med. 2004;164:83–91. doi: 10.1001/archinte.164.1.83.
    1. Ellenberg SS. Informed consent: protection or obstacle? Some emerging issues. Control Clin Trials. 1997;18:628–636. doi: 10.1016/S0197-2456(96)00130-4.
    1. Adamson J, Cockayne S, Puffer S, Torgerson DJ. Review of randomised trials using the post-randomised consent (Zelen's) design. Contemp Clin Trials. 2006;27:305–319. doi: 10.1016/j.cct.2005.11.003.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj